Tris Pharma, Inc.
https://www.trispharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tris Pharma, Inc.
Endo En Route To NYSE With Common Stock Exchange Expected Later In 2024
Endo continues to stride its financial revival path, with the latest plans to list common stock on the NYSE. Also, the firm has just launched a generic tiopronin rival to Travere Therapeutics' Thiola.
Finance Watch: NGM Reemerges With $122m During Post-July 4th VC Mega-Round Boom
Private Company Edition: After its acquisition by an investor earlier this year, NGM Bio has raised a $122m series A round, adding to a recent surge in large venture capital financings. Also, Vanqua Bio disclosed $45m in new funding and Renalys completed a $38.4m series A.
BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More
Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.
BIO Notebook: US FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More
Insights from Day Two of the BIO International Convention in San Diego include user fees potentially supporting the FDA's AI ambitions, the evolving pros and cons of partnering, and J&J's view on dealmaking in 2024.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- NextWave Pharmaceuticals
- Park Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice